Sign in
TerminatedNo phase

Pregnancy Outcomes and Maternal Insulin Sensitivity

Key facts

Who runs it
University Medical Center Groningen
Where
Netherlands2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
People taking part
30 people enrolled
Started
6 Feb 2020
Ended
8 Jul 2024
Type of study
Observational
Treatments tested
  • meal tolerance test
Record updated
30 March 2025
Why it stopped
slow recruitment, reached sufficient recruitment numbers for exploratory analysis

Who can take part

Age
18 years to 45 years
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Healthy singleton pregnant women (10-12 weeks of gestation)
  • BMI ≥25 kg/m2
  • FPG ≤7.0 mmol/l
  • Dutch or English speaking
  • Written informed consent

Who cannot take part

  • Participation in any other studies involving the investigation of medication or nutritional products or severe illness or antibiotic use in the two weeks prior to entry into the study
  • HIV/Hepatitis
  • Known allergies or intolerances for one or more nutritional ingredients in the MTT
  • Serious health complications (Hypertension, Hyperlipidemia, Asthma, Haemochromatosis) or medication use that influence the glucose metabolism or fetal growth (e.g. corticosteroids)
  • pre-existing Diabetes type 1 and 2 defined as FPG ≥7.0 mmol/l or use of diabetes medication
  • Multiple pregnancy
  • Expectation of non-compliance to the study protocol, among others, a fear of needles
  • Psychological dysfunctions

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The PROMIS study will focus on maternal insulin sensitivity thourghout pregnancy and postpartum in a moderate to high risk population (BMI ≥25 kg/m2) in developing adverse pregnancy outcomes. Next to the OGTT, the meal tolerance test (MTT) will be used as a tool for metabolic testing.

Read full original descriptionShow less

The investigators hypothesize that (early) pregnancy assessment of maternal glucose-insulin metabolism with a MTT in a moderate to high risk group identify more mothers at risk for adverse pregnancy outcomes compared with standard OGTT testing at 24-28 weeks.

The group in the trial

  • Healthy women pregnant of singleton with a BMI ≥25 kg/m2

    Healthy women pregnant of singleton with a BMI ≥25 kg/m2 will be followed from 12 weeks of gestation till 6 months postpartum. Neonates will be followed from birth up to 6 months of age.

    Treatment: meal tolerance test

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Publications
Record updated
30 March 2025